CLDX
美股周三早盘Celldex Therapeutics(CLDX)股价重挫9.5%其Barzolvolimab药物二期试验虽达到主要终点但未能改善嗜酸性食管炎(EoE)症状。
时间:2025-08-20 22:25:11 市场: 美股 综合
Point72 Asset Management Lp Reports 6.7% Passive Stake in Celldex Therapeutics Inc as of July 2 - SEC Filing
时间:2025-07-11 04:12:59 市场: 美股 综合
Celldex Therapeutics Inc : UBS Initiates Coverage With Buy Rating and Target Price $44
时间:2025-02-13 22:15:35 市场: 美股 综合
Celldex Therapeutics Inc : Citigroup Initiates Coverage With Buy Rating; Price Target $70
时间:2024-10-07 18:36:04 市场: 美股 综合
Celldex Therapeutics Inc : Wells Fargo Raises to Overweight From Equal Weight
时间:2024-09-26 17:51:58 市场: 美股 综合
Celldex Therapeutics Presents Landmark 52 Week Results From Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at Eadv 2024
时间:2024-09-25 22:45:00 市场: 美股 综合